These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Bueno L; de Ponti F; Fried M; Kullak-Ublick GA; Kwiatek MA; Pohl D; Quigley EM; Tack J; Talley NJ Neurogastroenterol Motil; 2007 Jan; 19(1 Suppl):89-119. PubMed ID: 17280587 [TBL] [Abstract][Full Text] [Related]
27. 5-HT receptors and visceral hypersensitivity - 2B or not 2B, that is the question? Grundy D Neurogastroenterol Motil; 2006 May; 18(5):339-42. PubMed ID: 16629859 [No Abstract] [Full Text] [Related]
28. Does irritable bowel syndrome really exist? Reactions to the proposed motility-based classification system. Whitehead WE Gastroenterology; 2003 Mar; 124(3):598. PubMed ID: 12612895 [No Abstract] [Full Text] [Related]
29. Motility in irritable-bowel syndrome. Müller-Lissner S; Coremans G; Dapoigny M; Pace F; Smout A; Stockbrügger RW; Tougas G; Whorwell PJ; Wienbeck M Digestion; 1997; 58(2):196-202. PubMed ID: 9144311 [No Abstract] [Full Text] [Related]
30. Novel therapies in the treatment of irritable bowel syndrome. Berrada D; Lembo T Expert Opin Investig Drugs; 2003 Apr; 12(4):635-45. PubMed ID: 12665418 [TBL] [Abstract][Full Text] [Related]
31. Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Cash BD; Chey WD Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1047-60. PubMed ID: 16305718 [TBL] [Abstract][Full Text] [Related]
32. [The efficacy of gastrotsepin in functional diseases of the large intestine]. Golovenko OV; Nazarov VA; Kirkin BV Klin Med (Mosk); 1995; 73(3):52-4. PubMed ID: 8577110 [No Abstract] [Full Text] [Related]
33. New and future drugs in nerve-gut dysfunction. Bueno L Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):794-801. PubMed ID: 10730572 [TBL] [Abstract][Full Text] [Related]
34. Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Terry N; Margolis KG Handb Exp Pharmacol; 2017; 239():319-342. PubMed ID: 28035530 [TBL] [Abstract][Full Text] [Related]
35. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Lesurtel M; Soll C; Graf R; Clavien PA Cell Mol Life Sci; 2008 Mar; 65(6):940-52. PubMed ID: 18080089 [TBL] [Abstract][Full Text] [Related]
36. The irritable bowel syndrome: motility, mind or message? Variations on an enigma. Quigley EM Dig Dis; 1994; 12(2):69-71. PubMed ID: 8045029 [No Abstract] [Full Text] [Related]
37. From the bench to the 'crib'-side: implications of scientific advances to paediatric neurogastroenterology and motility. Chitkara DK; Di Lorenzo C Neurogastroenterol Motil; 2006 Apr; 18(4):251-62. PubMed ID: 16553581 [TBL] [Abstract][Full Text] [Related]
38. [Role of serotonin in the pathophysiology of the irritable bowel syndrome]. Moskwa A; Boznańska P Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558 [TBL] [Abstract][Full Text] [Related]
39. [Motility disorders in diseases of the colon. Pathogenetic and clinical aspects]. Rostad H Tidsskr Nor Laegeforen; 1975 Dec; 95(34-36):1957-60. PubMed ID: 1209566 [No Abstract] [Full Text] [Related]
40. Pediatric gastrointestinal motility--future directions and challenges. Youssef NN; Di Lorenzo C Dig Dis; 2006; 24(3-4):308-12. PubMed ID: 16849858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]